Cargando…

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)

Patients with multiple myeloma-bearing translocation t(11;14) have recently been shown to benefit from the apoptosis-inducing drug venetoclax; however, the drug lacks FDA approval in multiple myeloma thus far due to a potential safety signal in the overall patient population. Selinexor is an inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Nina, Chaudhry, Sana, Totiger, Tulasigeri M., Diaz, Robert, Roberts, Evan, Montoya, Skye, Pardo, Gabriel, Pardo, Alejandro, Afaghani, Jumana, Affer, Maurizio, Jahn, Jacob, Bradley, Terrence, Maura, Francesco, Kazandjian, Dickran, Bilbao, Daniel, Chapman, Jennifer, Landgren, Ola, Hoffman, James, Taylor, Justin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581939/ https://www.ncbi.nlm.nih.gov/pubmed/36261486 http://dx.doi.org/10.1038/s41698-022-00315-2

Ejemplares similares

Protein biomarkers for response to XPO1 inhibition in haematologic malignancies
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
por: Kaufman, Jonathan L., et al.
Publicado: (2021)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021)

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
por: Szita, Virág Réka, et al.
Publicado: (2022)

Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
por: Basali, Diana, et al.
Publicado: (2020)

Targeted Therapy Development in Acute Myeloid Leukemia
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

PB1872: SELINEXOR IN COMBINATION WITH VENETOCLAX AND HYPOMETHYLATING AGENTS FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE CO-MORBIDITIES
por: Chen, Fangli, et al.
Publicado: (2023)

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation
por: Diamantidis, Michael D., et al.
Publicado: (2022)

Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report
por: Yang, Yang, et al.
Publicado: (2021)

The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response
por: Yuan, Sheng, et al.
Publicado: (2023)

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
por: Bahlis, Nizar J., et al.
Publicado: (2021)

The chromosome translocation (11;14)(p13;q11) associated with T cell acute leukemia. Asymmetric diversification of the translocational junctions
Publicado: (1990)

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019)

Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapy—Proof-of-Concept Animal Study
por: Spieler, Benjamin, et al.
Publicado: (2022)

Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity
por: Todoerti, Katia, et al.
Publicado: (2021)

Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
por: Fatoki, Raleigh Ayoolu, et al.
Publicado: (2022)

Selinexor for multiple myeloma
Publicado: (2022)

P577: EFFICACY OF SELINEXOR COMBINED WITH A HYPOMETHYLATING AGENT IN THE TREATMENT OF REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA IN PATIENTS EXPOSED TO VENETOCLAX
por: Zhang, Jian, et al.
Publicado: (2023)

Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes
por: Jiang, Jiqian, et al.
Publicado: (2023)

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients
por: Kazandjian, Dickran, et al.
Publicado: (2019)

Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2022)

Toward prediction of abscopal effect in radioimmunotherapy: Pre-clinical investigation
por: Mihaylov, Ivaylo B., et al.
Publicado: (2021)

Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review
por: Valliani, Salimah, et al.
Publicado: (2020)

Near tetrapoloid karyotype with translocation t(11;14) in a Moroccan patient with amyloid light-chain amyloidosis and multiple myeloma
por: Hamdaoui, Hasna, et al.
Publicado: (2020)

Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature
por: Abuelgasim, Khadega A., et al.
Publicado: (2020)

Induction of t(11;14) IgH enhancer/promoter-cyclin D1 gene translocation using CRISPR/Cas9
por: Tsuyama, Naohiro, et al.
Publicado: (2019)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Selinexor and COVID-19: The Neglected Warden
por: Mostafa-Hedeab, Gomaa, et al.
Publicado: (2022)

Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study
por: Ni, Ivyna Bong Pau, et al.
Publicado: (2012)

Multiple myeloma with t(11;14): impact of novel agents on outcome
por: Puertas, Borja, et al.
Publicado: (2023)

Chromosomal translocation t(11;14) and p53 deletion induced by the CRISPR/Cas9 system in normal B cell-derived iPS cells
por: Azami, Yusuke, et al.
Publicado: (2021)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice
por: Stiff, Patrick J., et al.
Publicado: (2023)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023)

Selinexor: Targeting a novel pathway in multiple myeloma
por: Mo, Clifton C., et al.
Publicado: (2023)

1114 Fetal demise during the COVID-19 pandemic: are rates increasing?
por: Ozimek, John A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g1do7bs1orp4hsbq2ovi83l2hg